Gene Delivery Technologies Market Report 2026

The gene delivery technologies market size has grown rapidly in recent years. It will grow from $4.29 billion in 2025 to $4.92 billion in 2026 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to growth in gene therapy research, development of viral vectors, academic research funding, use of electroporation techniques, vaccine development programs.

The gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $8.46 billion in 2030 at a compound annual growth rate (CAGR) of 14.5%. The growth in the forecast period can be attributed to expansion of gene therapy pipelines, innovation in delivery vectors, demand for safer delivery methods, growth in cell therapy applications, increased clinical trial activity. Major trends in the forecast period include rising use of viral and non-viral delivery systems, increased adoption in gene and cell therapy, expansion of lipid nanoparticle technologies, growing focus on targeted gene delivery, advancements in physical gene transfer methods.

The growing number of cell and gene therapies is expected to drive the expansion of the gene delivery technologies market in the coming years. Cell and gene therapies are medical treatments that aim to cure or manage diseases by modifying a patient’s genetic and cellular makeup. The rise in these therapies is largely fueled by advancements in gene editing technologies, which play a crucial role in the development and commercialization of cell and gene therapies. For example, in March 2025, IQVIA, a US-based provider of advanced analytics, technology solutions, and contract research services, reported that new CAR T trial starts reached 199 in 2024, while gene therapy trial starts reached 130, representing increases of 54% and 65%, respectively. Therefore, the increasing adoption of cell and gene therapies is driving the gene delivery technologies market.

Leading companies in the gene delivery technologies market are developing advanced products, such as the ProteoAnalyzer, to strengthen their market position. The ProteoAnalyzer is an automated system from Agilent Technologies designed for protein analysis, utilizing parallel capillary electrophoresis (CE) technology. For instance, in July 2024, Agilent Technologies Inc., a US-based life sciences company, launched the ProteoAnalyzer system. This platform enables rapid, high-resolution protein analysis with minimal sample consumption, which is particularly valuable for researchers working with complex protein mixtures in pharmaceuticals, biopharma, and bioengineered food ingredients. The system allows for detailed analysis of protein mixtures, supporting the development of therapeutic proteins and accelerating translational research.

In January 2024, Kyowa Kirin Co. Ltd., a Japan-based pharmaceutical company, acquired Orchard Therapeutics plc for an undisclosed amount. Through this acquisition, Kyowa Kirin aims to strengthen its gene therapy portfolio by leveraging Orchard Therapeutics’ expertise in hematopoietic stem cell (HSC) gene therapies, targeting rare genetic diseases and expanding patient access to transformative treatments. Orchard Therapeutics plc, a UK-based biopharmaceutical company, specializes in gene therapy.

Major companies operating in the gene delivery technologies market are Thermo Fisher Scientific Inc., QIAGEN NV, Horizon Discovery Group Co, OriGene Technologies Inc., Oxford Biomedica Solutions LLC, SignaGen Laboratories LLC, Vectalys SAS, Takara Bio Inc., Bio-Rad Laboratories Inc., System Biosciences LLC, Promega Corporation, Catalent Inc., Pfizer Inc., Becton Dickinson and Company, Novartis AG, Intellia Therapeutics Inc., Editas Medicine Inc., CRISPR Therapeutics AG, Spark Therapeutics Inc., Bluebird Bio Inc., Sarepta Therapeutics Inc., Beam Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Moderna Inc., BioNTech SE, Translate Bio Inc., CureVac N.V., Lonza Group AG.

North America was the largest region in the gene delivery technologies market in 2025.Asia-Pacific is expected to be the fastest-growing region in the global gene delivery technologies market report during the forecast period. The regions covered in the gene delivery technologies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gene delivery technologies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gene delivery technologies market by increasing costs of imported vectors, reagents, and specialized laboratory equipment. Biotechnology companies and research institutions are most affected due to reliance on imported components. These tariffs raise research costs by increasing expenses for vector development, testing, and scale-up activities, potentially slowing innovation timelines. However, they encourage local manufacturing of delivery technologies, supporting domestic capabilities in viral and non-viral gene delivery platforms.

The gene delivery technologies market research report is one of a series of new reports that provides gene delivery technologies market statistics, including gene delivery technologies industry global market size, regional shares, competitors with a gene delivery technologies market share, detailed gene delivery technologies market segments, market trends and opportunities, and any further data you may need to thrive in the gene delivery technologies industry. This gene delivery technologies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gene delivery technologies refer to techniques used to introduce foreign genetic material, such as DNA or RNA, into cells, with the objective of transferring the genetic material into the target cells. These technologies are commonly employed to treat diseases or disorders caused by genetic mutations or inherited genes.

The main types of gene delivery technology modes are biological, chemical, and physical. Biological methods involve the use of living organisms or their products in the development and delivery of gene therapy products. The approaches include ex vivo, in vivo, and in vitro, and are applied in gene therapy, cell therapy, vaccines, and research.

The gene delivery technologies market consists of revenues earned by entities by providing services such as viral vector production, gene editing, gene therapy, and cell therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Gene delivery technologies also include sales of viral and non-viral vectors, transfection reagents, and gene editing tools that are used in providing gene delivery. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.